Adverse events associated with Pegaspargase biosimilar in pediatric patients with acute lymphoblastic leukemia: A prospective single-center study.

Bijoy Kumar PandaMahima GaikwadVibha BafnaNeela VaidyaVishal AundheAngha Mhatre

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Bio-similar Pegaspargase in combination with chemotherapy was safe and tolerable in the pediatric ALL patients treated according to ICiCLe ALL-14 protocol. Suspected AEs ranged from mild to moderate and hepatic failure and hyperglycemia being severe.

Keyphrases

acute lymphoblastic leukemia
randomized controlled trial
pulmonary embolism
early onset
locally advanced
radiation therapy
young adults
acute myeloid leukemia
drug induced
chemotherapy induced